Mie Linder Hübbe

PhD defence by Mie Linder Hübbe

On 31 January, PhD student Mie Linder Hübbe will defend her PhD thesis "Preclinical evaluation of adoptive T cell therapy and liposomal tumour antigen vaccination as a combinatorial cancer immunotherapy"

Time: 13:00
Place: Technical University of Denmark, build. 341, aud. 23

Principal supervisor: Professor Thomas Lars Andresen
Co-supervisor: Assistant Professor Joseph John Kaplinsky

Senior Researcher Ladan Parhamifar, DTU Health Tech
Associate Professor Emil Kofod-Olsen, Aalborg University
Head of Immunomonitoring Else Marit Inderberg, Oslo University Hospital

Chairperson at defence: Associate Professor Andrew Urquhart

Cancer cells have acquired genetic mutations that make them grow uncontrollably and appear differently than healthy cells. This allows the immune system to recognize cancer cells as objects that must be eliminated to avoid disease. However, cancer cells often acquire abilities that enable them to escape an attack by the immune system. This has inspired the development of cancer immunotherapies that activate immune cells to help them fight the cancer cells. T cells are essential players in this aspect because they can kill cancer cells directly. The ultimate goal of cancer immunotherapies is therefore to stimulate a T cell response against the cancer cells. One way to achieve this is to increase the number of cancer-reactive T cells by isolating them from a patient, expand them in the laboratory and thereafter give them to the patient. This is called T cell therapy and it is an effective treatment for some patients with melanoma or leukemia. However, most patients are not cured by T cell therapy and it is therefore necessary to identify ways to improve the treatment.
Studies have shown that the effect of T cell therapy can be enhanced by a vaccination against the cancer cells. These cancer vaccines are typically injected as a depot in muscle or under the skin, but studies have suggested that this way of injecting the vaccine can induce death of T cells that are attracted to the depot. To circumvent this issue, we developed a novel cancer vaccine delivery system that can be given directly into the blood stream. Our delivery system is based on a nanoparticle that carries the vaccine components on its surface. In this PhD project we show that we can enhance the effect of T cell therapy by combining the T cells with our cancer vaccine in mice. The combination of T cell therapy and vaccine results in a prolonged survival of mice with cancer, and the vaccine effectively increases the amount of the cancer-reactive T cells. This ability to increase the number of cancer-reactive T cells after treatment offer an opportunity to decrease the time spent on expanding the number of T cells in the laboratory. In theory, this can be translated into a shorter waiting time for cancer patients to receive their T cell therapy. Together these findings suggest that our cancer vaccine delivery system can be used in combination with T cell therapy to improve the effect, and hopefully contribute to a better and faster treatment for more cancer patients in the future.


Fri 31 Jan 20
13:00 - 16:00


DTU Sundhedsteknologi


Technical University of Denmark, build. 341, aud. 23